Aelis Farma Reports 2025 Half-Year Financial Results and Presents Progress and Development Outlook

About this update from Aelis Farma Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/be8ccdd09ea24fa7d6af12fd7d18b895"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4TL1gIAtbQU6SgtnUGCjlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/be8ccdd09ea24fa7d6af12fd7d18b895","width":480,"height":252}},"lazy":false},{"type":"text","content":"The first half of 2025 was marked by:","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The publication of the final analysis of the pioneering Phase 2b clinical trial in cannabis use disorders (CUD) with the CB1-SSi AEF0117, which further validated the new pharmacological class of CB1-SSi by confirming the compound’s safety and its ability to reduce cannabis consumption, although the primary endpoint was not reached.","length":333,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":333,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Significant progress in preparing the multicentre Phase 2b study with AEF0217 for the treatment of behavioural deficits associated with Down syndrome, which is scheduled to start in the second half of 2025, in line with the announced plan.","length":239,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":239,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Rigorous cost management, resulting in a solid cash position of €10.8 million as of 30 June 2025, providing financial visibility beyond 2026, which could be further extended through additional non-dilutive funding.","length":214,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":214,"olType":false},{"type":"text","content":"BORDEAUX, France, September 22, 2025--(BUSINESS WIRE)--Regulatory News:","length":71,"tagName":"p"},{"type":"text","content":"Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its financial results for the first half of 2025 and provides a business update.","length":297,"tagName":"p"},{"type":"text","content":"Pie...

More updates from Aelis Farma Sa